<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Frovatriptan</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00998</strong>&#160; (APRD00270)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>Frovatriptan (Frova&#174;) is a triptan drug developed by Vernalis for the treatment of migraine headaches, in particular those associated with menstruation. The product is licensed to Endo Pharmaceuticals in North America and Menarini in Europe.<sup class="footnote" id="fnr1"><a href="#fn1">1</a></sup> Frovatriptan causes vasoconstriction of arteries and veins that supply blood to the head. It is available as 2.5 mg tablets.</p>
<p>Frovatriptan has mean terminal elimination half-life of approximately 26 hours, which is substantially longer than other triptans.</p>
<p>Frovatriptan is available only by prescription in the United States, where a secondary New Drug Approval (sNDA) was filed in July 2006<sup class="footnote" id="fnr2"><a href="#fn2">2</a></sup> and which is currently pending.<sup class="footnote" id="fnr3"><a href="#fn3">3</a></sup> The <span class="caps">FDA</span> anticipates completing its review of this application on or before the current <span class="caps">PDUFA</span> (Prescription Drug User Fee Act) review date of August 19, 2007. If the sNDA is approved, Frova&#174; will be the only medication indicated in the U.S. for the short-term prevention of menstrual migraine (MM).</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00998/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00998/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00998.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00998.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00998.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00998.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00998.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00998">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Frovatriptan succinate</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Frova</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Frovelan</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Miguard</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/serotonin-receptor-agonists">Serotonin Receptor Agonists</a></li>
<li><a href="/mesh/anti-migraine-agents">Anti-migraine Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>158747-02-5</td></tr><tr><th>Weight</th><td>Average: 243.3043<br>Monoisotopic: 243.137162181</td></tr><tr><th>Chemical Formula</th><td>C<sub>14</sub>H<sub>17</sub>N<sub>3</sub>O</td></tr><tr><th>InChI Key</th><td>XPSQPHWEGNHMSK-SECBINFHSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C14H17N3O/c1-16-9-3-5-13-11(7-9)10-6-8(14(15)18)2-4-12(10)17-13/h2,4,6,9,16-17H,3,5,7H2,1H3,(H2,15,18)/t9-/m1/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">(3R)-3-(methylamino)-2,3,4,9-tetrahydro-1H-carbazole-6-carboxamide</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CN[C@@H]1CCC2=C(C1)C1=C(N2)C=CC(=C1)C(N)=O</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Indoles and Derivatives</td></tr><tr><th>Subclass</th><td>Carbazoles</td></tr><tr><th>Direct parent</th><td>Carbazoles</td></tr><tr><th>Alternative parents</th><td>Indolecarboxamides and Derivatives; Benzamides; Indoles; Benzoyl Derivatives; Pyrroles; Primary Carboxylic Acid Amides; Enolates; Carboxylic Acids; Dialkylamines; Polyamines</td></tr><tr><th>Substituents</th><td>benzamide; indole; benzoyl; benzene; pyrrole; primary carboxylic acid amide; carboxamide group; secondary amine; enolate; carboxylic acid derivative; secondary aliphatic amine; carboxylic acid; polyamine; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the carbazoles. These are compounds containing a three ring system containing a pyrrole ring fused on either side to a benzene ring.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the acute treatment of migraine attacks with or without aura in adults.</td></tr><tr><th>Pharmacodynamics</th><td>Frovatriptan is a second generation triptan 5-HT receptor agonist that binds with high affinity for 5-HT<sub>1B</sub> and 5-HT<sub>1D</sub> receptors. It is structurally distinct from, but pharmacologically related to other selective 5-HT<sub>1B/1D</sub> receptor agonists. Frovatriptan has no significant effects on GABA<sub>A</sub> mediated channel activity and has no significant affinity for benzodiazepine binding sites. Frovatriptan is believed to act on extracerebral, intracranial arteries and to inhibit excessive dilation of these vessels in migraine. Research has shown that migraine can be caused by the swelling of blood vessels around the brain. Frovatriptan eases the pain associated with migraine by narrowing these blood vessels. Frovatriptan has one of the highest affinities for the 5-HT<sub>1B</sub> of the second-generation triptan agonists.</td></tr><tr><th>Mechanism of action</th><td>Three distinct pharmacological actions have been implicated in the antimigraine effect of the triptans: (1) stimulation of presynaptic 5-HT<sub>1D</sub> receptors, which serves to inhibit both dural vasodilation and inflammation; (2) direct inhibition of trigeminal nuclei cell excitability via 5-HT<sub>1B/1D</sub> receptor agonism in the brainstem and (3) vasoconstriction of meningeal, dural, cerebral or pial vessels as a result of vascular 5-HT<sub>1B</sub> receptor agonism.</td></tr><tr><th>Absorption</th><td>Frovatriptan is rapidly absorbed from the duodenum, but has low oral bioavailability.</td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>4.2 L/kg [males]</li>
	<li>3 L/kg [females]</li>
</ul></td></tr><tr><th>Protein binding</th><td>Binding to serum proteins is low (approximately 15%). Reversible binding to blood cells at equilibrium is approximately 60%.</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>In vitro, cytochrome P450 1A2 appears to be the principal enzyme involved in the metabolism of frovatriptan to several metabolites including hydroxylated frovatriptan, N-acetyl desmethyl frovatriptan, hydroxylated N-acetyl desmethyl frovatriptan and desmethyl frovatriptan, and several other minor metabolites. Desmethyl frovatriptan has lower affinity for 5-HT<sub>1B/1D</sub> receptors compared to the parent compound. The N-acetyl desmethyl metabolite has no significant affinity for 5-HT receptors. The activity of the other metabolites is unknown.</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Frovatriptan</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00830">desmethyl frovatriptan</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/851">Details</a></td></tr><tr><td>Frovatriptan</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00885">Hydroxylated frovatriptan</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/906">Details</a></td></tr><tr><td>Frovatriptan</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00886">Hydroxylated N-acetyl desmethyl frovatriptan</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/907">Details</a></td></tr><tr><td>Frovatriptan</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00921">N-acetyl desmethyl frovatriptan</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/942">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>Radiolabeled compounds excreted in urine were unchanged frovatriptan, hydroxylated frovatriptan, N-acetyl desmethyl frovatriptan, hydroxylated N-acetyl desmethyl frovatriptan and desmethyl frovatriptan, together with several other minor metabolites. Less than 10% of frovatriptan was excreted in urine after an oral dose.</td></tr><tr><th>Half life</th><td>26 hours</td></tr><tr><th>Clearance</th><td><ul>
	<li>220 mL/min [male receiving IV dose of 0.8 mg]</li>
	<li>130 mL/min [Female receiving IV dose of 0.8 mg]</li>
</ul></td></tr><tr><th>Toxicity</th><td>There is no direct experience of any patient taking an overdose of Frovatriptan. The maximum single dose of frovatriptan given to male and female patients with migraine was 40 mg (16 times the clinical dose) and the maximum single dose given to healthy male subjects was 100 mg (40 times the clinical dose) without significant adverse events.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="snp-fx"><thead><tr><th>Interacting Gene/Enzyme</th><th>SNP RS ID</th><th>Allele name</th><th>Defining change</th><th>Effect</th><th>Reference(s)</th></tr></thead><tbody><tr><td>Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-3<br>Gene symbol: GNB3<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/P16520" target="_blank">P16520 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs5443" target="_blank">rs5443 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><span class="wishart wishart-not-available">Not Available</span></td><td>T Allele</td><td>Better response to drug treatment</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/17361120" target="_blank" title="Schurks M, Kurth T, Stude P, Rimmbach C, de Jesus J, Jonjic M, Diener HC, Rosskopf D: G protein beta3 polymorphism and triptan response in cluster headache. Clin Pharmacol Ther. 2007 Oct;82(4):396-401. Epub 2007 Mar 14.">17361120 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr></tbody></table></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9934</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.986</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.5794</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.602</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8862</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.7244</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.6147</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7785</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9116</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.5</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Inhibitor</td>
        <td>0.6997</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8842</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8614</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.6656</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.5316</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>High CYP Inhibitory Promiscuity</td>
        <td>0.5744</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.7623
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9456
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9406
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          1.9582 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9878
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Inhibitor 
        </td>
        <td>
            0.6428
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Endo pharmaceuticals inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li>DispenseXpress Inc.</li>
<li><a href="http://www.elan.com">Elan Pharmaceuticals Inc.</a></li>
<li><a href="http://www.endo.com">Endo Pharmaceuticals Inc.</a></li>
<li><a href="http://www.pdms-almac.com">Pharmaceutical Development and Manufacturing Services Ltd.</a></li>
<li><a href="http://statrxusa.exporterus.com">Stat Rx Usa</a></li>
<li><a href="http://ir.wcrx.com">Warner Chilcott Co. Inc.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr><th>Prices</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="prices"><thead><tr><th>Unit description</th><th>Cost</th><th>Unit</th></tr></thead><tbody><tr><td>Frova 9 2.5 mg tablet Box</td><td>262.31USD</td><td>box</td></tr><tr><td>Frova 2.5 mg tablet</td><td>33.73USD</td><td>tablet</td></tr></tbody></table><div class="alert alert-warning clearfix">DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.</div></td></tr><tr><th>Patents</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="patents"><thead><tr><th>Country</th><th>Patent Number</th><th>Approved</th><th>Expires (estimated)</th></tr></thead><tbody><tr><td>United States</td><td>5464864</td><td>1995-11-07</td><td>2015-11-07</td></tr><tr><td>United States</td><td>5962501</td><td>1993-12-16</td><td>2013-12-16</td></tr><tr><td>Canada</td><td>2113726</td><td>2008-02-19</td><td>2012-06-17</td></tr><tr><td>Canada</td><td>2152630</td><td>2005-07-26</td><td>2013-12-16</td></tr></tbody></table></td></tr><tr id="properties"><th class="divider" colspan="2">Properties</th></tr><tr><th>State</th><td>solid</td></tr><tr><th>Experimental Properties</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr><tr><td>water solubility</td><td>Soluble</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>logP</td><td>0.9</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></table></td></tr><tr><th>Predicted Properties</th><td class="data-table-container"><table class="table table-condensed table-striped"><thead><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr></thead><tbody><tr><td>water solubility</td><td>1.23e-01 g/l</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>1.2</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>1.08</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#logp_logd">ChemAxon</a></td></tr><tr><td>logS</td><td>-3.3</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>pKa (strongest acidic)</td><td>14.54</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>pKa (strongest basic)</td><td>10.42</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>physiological charge</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>hydrogen acceptor count</td><td>2</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>hydrogen donor count</td><td>3</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>polar surface area</td><td>70.91</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topolgical_surface">ChemAxon</a></td></tr><tr><td>rotatable bond count</td><td>2</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>refractivity</td><td>71.84</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#refractivity">ChemAxon</a></td></tr><tr><td>polarizability</td><td>27.55</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>number of rings</td><td>3</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>bioavailability</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>rule of five</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Ghose filter</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Veber's rule</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>MDDR-like rule</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="references"><th class="divider" colspan="2">References</th></tr><tr><th>Synthesis Reference</th><td><span class="citations"><p>Samir Naik, Anthony Crasto, Narendra Joshi, Sachin Srivastava, &#8220;Amorphous frovatriptan succinate and process for the preparation thereof.&#8221; U.S. Patent US20070299123, issued December 27, 2007.</p></span><a class="wishart-link-out" href="https://www.google.com/?tbm=pts#q=20070299123&amp;tbm=pts" target="_blank">US20070299123 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><th>General Reference</th><td><span class="citations"><ol>
	<li>Markus F, Mikko K: Frovatriptan review. Expert Opin Pharmacother. 2007 Dec;8(17):3029-33. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18001261">Pubmed</a></li>
	<li>Easthope SE, Goa KL: Frovatriptan. <span class="caps">CNS</span> Drugs. 2001;15(12):969-76; discussion 977-8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11735616">Pubmed</a></li>
	<li>Balbisi EA: Frovatriptan: a review of pharmacology, pharmacokinetics and clinical potential in the treatment of menstrual migraine. Ther Clin Risk Manag. 2006 Sep;2(3):303-8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18360605">Pubmed</a></li>
	<li>Balbisi EA: Frovatriptan succinate, a 5-HT1B/1D receptor agonist for migraine. Int J Clin Pract. 2004 Jul;58(7):695-705. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15311727">Pubmed</a></li>
	<li>Elkind AH, Wade A, Ishkanian G: Pharmacokinetics of frovatriptan in adolescent migraineurs. J Clin Pharmacol. 2004 Oct;44(10):1158-65. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15342617">Pubmed</a></li>
	<li>Jhee SS, Shiovitz T, Crawford AW, Cutler NR: Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: a comparative review. Clin Pharmacokinet. 2001;40(3):189-205. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11327198">Pubmed</a></li>
</ol></span></td></tr><tr><th>External Links</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Resource</th><th>Link</th></tr></thead><tbody><tr><td>PubChem Compound</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=77992" target="_blank">77992 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PubChem Substance</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46506288" target="_blank">46506288 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChemSpider</td><td><a class="wishart-link-out" href="http://www.chemspider.com/Chemical-Structure.70378.html" target="_blank">70378 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>BindingDB</td><td><a class="wishart-link-out" href="http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50073689" target="_blank">50073689 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Therapeutic Targets Database</td><td><a class="wishart-link-out" href="http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000063" target="_blank">DAP000063 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PharmGKB</td><td><a class="wishart-link-out" href="http://www.pharmgkb.org/drug/PA164754891" target="_blank">PA164754891 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>RxList</td><td><a class="wishart-link-out" href="http://www.rxlist.com/cgi/generic3/frova.htm" target="_blank">http://www.rxlist.com/cgi/generic3/frova.htm <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drugs.com</td><td><a class="wishart-link-out" href="http://www.drugs.com/cdi/frovatriptan.html" target="_blank">http://www.drugs.com/cdi/frovatriptan.html <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PDRhealth</td><td><a class="wishart-link-out" href="http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/fro1622.shtml" target="_blank">http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/fro1622.shtml <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Wikipedia</td><td><a class="wishart-link-out" href="http://en.wikipedia.org/wiki/Frovatriptan" target="_blank">Frovatriptan <span class="glyphicon glyphicon-new-window"> </span></a></td></tr></tbody></table></td></tr><tr><th>ATC Codes</th><td>N02CC07<ul class="atc-drug-tree"><li><a href="/atc/N#N">N &#8212; NERVOUS SYSTEM</a></li><li><a href="/atc/N02#N02">N02 &#8212; ANALGESICS</a></li><li><a href="/atc/N02C#N02C">N02C &#8212; ANTIMIGRAINE PREPARATIONS</a></li><li><a href="/atc/N02CC#N02CC">N02CC &#8212; Selective serotonin (5HT1) agonists</a></li></ul></td></tr><tr><th>AHFS Codes</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>PDB Entries</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>FDA label</th><td><a href="/system/fda_labels/DB00998.pdf?1265922808">show</a>(871 KB)</td></tr><tr><th>MSDS</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00215">Citalopram</a></td><td>Increased risk of CNS adverse effects</td></tr><tr><td><a href="/drugs/DB06700">Desvenlafaxine</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00320">Dihydroergotamine</a></td><td>Possible severe and prolonged vasoconstriction</td></tr><tr><td><a href="/drugs/DB01253">Ergonovine</a></td><td>Possible severe and prolonged vasoconstriction</td></tr><tr><td><a href="/drugs/DB00696">Ergotamine</a></td><td>Possible severe and prolonged vasoconstriction</td></tr><tr><td><a href="/drugs/DB01175">Escitalopram</a></td><td>Increased risk of CNS adverse effects</td></tr><tr><td><a href="/drugs/DB00472">Fluoxetine</a></td><td>Increased risk of CNS adverse effects</td></tr><tr><td><a href="/drugs/DB00176">Fluvoxamine</a></td><td>Increased risk of CNS adverse effects</td></tr><tr><td><a href="/drugs/DB00353">Methylergometrine</a></td><td>Possible severe and prolonged vasoconstriction</td></tr><tr><td><a href="/drugs/DB00247">Methysergide</a></td><td>Possible severe and prolonged vasoconstriction</td></tr><tr><td><a href="/drugs/DB01149">Nefazodone</a></td><td>Increased risk of CNS adverse effects</td></tr><tr><td><a href="/drugs/DB00715">Paroxetine</a></td><td>Increased risk of CNS adverse effects</td></tr><tr><td><a href="/drugs/DB01104">Sertraline</a></td><td>Increased risk of CNS adverse effects</td></tr><tr><td><a href="/drugs/DB01105">Sibutramine</a></td><td>Increased risk of CNS adverse effects</td></tr><tr><td><a href="/drugs/DB00193">Tramadol</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00752">Tranylcypromine</a></td><td>Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome. </td></tr><tr><td><a href="/drugs/DB00656">Trazodone</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00726">Trimipramine</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. </td></tr><tr><td><a href="/drugs/DB00285">Venlafaxine</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00315">Zolmitriptan</a></td><td>Concomitant use of two serotonin 5-HT1D receptor agonists, such as zolmitriptan and frovatriptan, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Food does not affect amount of absorption but delays maximal levels by about 1 hour.</li>
<li>Take without regard to meals.</li></ul></td></tr></tbody></table>